Descriptive only
Discontinuation due to adverse events
Parkinson disease
longest follow-upRecorded harmsEach dose separatelyHazard ratio (from event counts)
1
Randomized trials
2
Treatments
194
Participants
9
Events
In plain language
No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 1 trial. The trial data below are shown as reported.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Baseline characteristics of the trials
The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.
| Trial | Sex (percent female) effect modifier, prognostic factor; 0 of 1 | Asian ancestry or region (percent Asian) effect modifier, prognostic factor; 0 of 1 |
|---|---|---|
| Exenatide-PD3 S001156 | not reported | not reported |
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- FlagBaseline, Sex: not reported by 1 of 1 trials
- FlagBaseline, Asian ancestry or region: not reported by 1 of 1 trials
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exenatide-PD3 | 96 | modified_itt | Treatment discontinuation for adverse events while staying in follow up | not stated | not stated | not stated | not stated | not stated | double_blind | non_industry | 2020 | Parkinson disease; age 25 to 80; Hoehn and Yahr 2.5 or less ON; stable dopaminergic therapy 4 weeks; MoCA 21 or more; PHQ-9 below 16 |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| Exenatide-PD3 | A1 | EXENER_SC_2MG_QW | 96 | arm, events | 8 / 97 | R0021160:Figure 1 | |||
| Exenatide-PD3 | A2 | PLACEBO | 96 | arm, events | 1 / 97 | R0021160:Figure 1 |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.